15:43 , Feb 8, 2017 |  BC Innovations  |  Translation in Brief

Homing immunotherapies

Chasing solid tumor resection with immunotherapy can prevent cancer recurrence by eliminating circulating tumor cells and microtumors, but the approach has low efficacy in some patients and runs the risk of systemic side effects. North...
08:00 , Dec 21, 2009 |  BioCentury  |  Product Development

Clavis and Clovis have a Clue

Clovis Oncology Inc. 's first deal fits the formula its managers described this spring when they set out to replicate their in-licensing success with Pharmion Corp. by taking advantage of new tools to direct drug...
07:00 , Aug 23, 2004 |  BioCentury  |  Tools & Techniques

Src sightings

Though it is the oldest known and one of the most studied proto-oncogenes, Src has wallowed in relative obscurity as a drug target compared to the developmental successes had by other kinase inhibitors. However, at...
08:00 , Feb 28, 2000 |  BioCentury  |  Emerging Company Profile

UroGenesys: Racing through prostate proteins

UroGenesys Inc. has developed a platform focused on finding proteins involved in urological diseases as fast as possible. In two years of work, the company has identified 40 proteins that meet strict criteria for differential...